David Arons
Overview
Explore the profile of David Arons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oliver K, Granero A, Berankova A, Miller C, Hindson C, La Haye C, et al.
Neurooncol Pract
. 2025 Feb;
12(1):5-18.
PMID: 39917767
Across the globe, significant inequities in brain tumor treatment, care, and support perpetuate. Identifying and addressing these unmet needs in the context of patients' rights is crucial to reducing inequalities...
2.
Horbinski C, Solomon D, Lukas R, Packer R, Brastianos P, Wen P, et al.
JAMA Oncol
. 2024 Dec;
PMID: 39724142
Importance: Molecular techniques, including next-generation sequencing, genomic copy number profiling, fusion transcript detection, and genomic DNA methylation arrays, are now indispensable tools for the workup of central nervous system (CNS)...
3.
Margol A, Molinaro A, Onar-Thomas A, Resnick A, Hanson D, Kieran M, et al.
J Clin Oncol
. 2024 Feb;
42(12):1340-1343.
PMID: 38394473
Why, when, and how to consider external control cohorts in pediatric brain tumor clinical trials.
4.
Budhu J, Chukwueke U, Jackson S, Lee E, McFaline-Figueroa J, Willmarth N, et al.
Neuro Oncol
. 2023 Dec;
26(4):596-608.
PMID: 38071654
Despite major strides in cancer research and therapy, these advances have not been equitable across race and ethnicity. Historically marginalized groups (HMG) are more likely to have inadequate preventive screening,...
5.
Singh K, Hotchkiss K, Parney I, de Groot J, Sahebjam S, Sanai N, et al.
Nat Med
. 2023 Jul;
29(10):2402-2405.
PMID: 37488293
No abstract available.
6.
Leeper H, Tonorezos E, Mayer D, Bakitas M, Chang S, Cooley M, et al.
Neurooncol Adv
. 2022 May;
4(1):vdac029.
PMID: 35542753
Background: Survivorship for those living with primary CNS cancers begins at diagnosis, continues throughout a person's life, and includes caregivers. Opportunities and challenges exist to advance survivorship care for those...
7.
Ellingson B, Gerstner E, Lassman A, Chung C, Colman H, Cole P, et al.
Neuro Oncol
. 2022 Apr;
24(8):1219-1229.
PMID: 35380705
Imaging response assessment is a cornerstone of patient care and drug development in oncology. Clinicians/clinical researchers rely on tumor imaging to estimate the impact of new treatments and guide decision...
8.
Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley M, et al.
Lancet Oncol
. 2021 Sep;
22(10):e456-e465.
PMID: 34592195
Integration of external control data, with patient-level information, in clinical trials has the potential to accelerate the development of new treatments in neuro-oncology by contextualising single-arm studies and improving decision...
9.
Dirven L, Vos M, Walbert T, Armstrong T, Arons D, van den Bent M, et al.
Neurooncol Pract
. 2021 Jul;
8(4):417-425.
PMID: 34277020
Background: The Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) working group aims to provide guidance on the use of PROs in brain tumor patients. PRO measures should be of high...
10.
Lee E, Selig W, Meehan C, Bacha J, Barone A, Bloomquist E, et al.
Neuro Oncol
. 2021 Apr;
23(8):1252-1260.
PMID: 33822177
On July 24, 2020, a workshop sponsored by the National Brain Tumor Society was held on innovating brain tumor clinical trials based on lessons learned from the COVID-19 experience. Various...